SALTON, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 5.713
AS - Asia 5.303
EU - Europa 5.022
SA - Sud America 672
AF - Africa 203
OC - Oceania 49
Continente sconosciuto - Info sul continente non disponibili 4
AN - Antartide 1
Totale 16.967
Nazione #
US - Stati Uniti d'America 5.469
SG - Singapore 1.839
IT - Italia 1.640
CN - Cina 1.143
PL - Polonia 848
VN - Vietnam 662
HK - Hong Kong 540
BR - Brasile 513
DE - Germania 406
KR - Corea 349
SE - Svezia 304
GB - Regno Unito 303
FR - Francia 298
NL - Olanda 252
FI - Finlandia 217
RU - Federazione Russa 176
IN - India 150
CA - Canada 105
IE - Irlanda 103
MX - Messico 98
BG - Bulgaria 92
TR - Turchia 82
JP - Giappone 69
AT - Austria 63
MA - Marocco 63
CH - Svizzera 59
BD - Bangladesh 55
ES - Italia 49
ID - Indonesia 48
IQ - Iraq 45
AR - Argentina 44
AU - Australia 41
PK - Pakistan 36
SA - Arabia Saudita 35
PH - Filippine 34
UA - Ucraina 34
BE - Belgio 33
ZA - Sudafrica 33
TW - Taiwan 32
CO - Colombia 29
TH - Thailandia 25
EC - Ecuador 21
UZ - Uzbekistan 21
IR - Iran 20
SI - Slovenia 20
SN - Senegal 20
CL - Cile 19
EG - Egitto 19
GR - Grecia 18
PT - Portogallo 17
VE - Venezuela 17
CZ - Repubblica Ceca 16
IL - Israele 13
AZ - Azerbaigian 12
RO - Romania 12
TN - Tunisia 12
AE - Emirati Arabi Uniti 11
LT - Lituania 11
MY - Malesia 11
JO - Giordania 10
DK - Danimarca 9
OM - Oman 9
PA - Panama 9
KE - Kenya 8
LK - Sri Lanka 8
PY - Paraguay 8
AO - Angola 7
CR - Costa Rica 7
DZ - Algeria 7
ET - Etiopia 7
KZ - Kazakistan 7
NZ - Nuova Zelanda 7
UY - Uruguay 7
BO - Bolivia 6
CI - Costa d'Avorio 6
HU - Ungheria 6
TT - Trinidad e Tobago 6
AL - Albania 5
BY - Bielorussia 5
KG - Kirghizistan 5
LB - Libano 5
NG - Nigeria 5
NO - Norvegia 5
NP - Nepal 5
PE - Perù 5
GT - Guatemala 4
HN - Honduras 4
PS - Palestinian Territory 4
YE - Yemen 4
DO - Repubblica Dominicana 3
EU - Europa 3
LU - Lussemburgo 3
LY - Libia 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
BA - Bosnia-Erzegovina 2
CG - Congo 2
CM - Camerun 2
EE - Estonia 2
GY - Guiana 2
Totale 16.924
Città #
Singapore 1.042
Ashburn 743
Warsaw 731
San Jose 632
Hong Kong 515
Chandler 440
Hefei 336
Seoul 332
Trieste 319
Beijing 265
Council Bluffs 230
Ho Chi Minh City 195
Boardman 171
Los Angeles 168
Fairfield 157
Hanoi 156
Dallas 139
London 139
Chicago 130
Lauterbourg 112
Columbus 111
Helsinki 102
Milan 100
Frankfurt am Main 94
Princeton 94
Zgierz 92
Seattle 90
The Dalles 90
Santa Clara 89
Sofia 89
Dublin 88
Houston 85
Woodbridge 85
Munich 81
Wilmington 81
Moscow 80
New York 77
Lappeenranta 69
Ann Arbor 66
São Paulo 60
Rome 55
Dong Ket 49
Casablanca 46
Redmond 45
Cambridge 43
Vienna 43
Montreal 42
Nuremberg 41
Tokyo 41
Denver 39
Turku 39
Buffalo 36
Orem 35
Haiphong 34
Amsterdam 33
Bern 31
Jacksonville 31
Manchester 31
Udine 31
North Bergen 30
Boydton 29
Redondo Beach 27
Chennai 26
Naples 26
Sydney 26
Da Nang 25
Shanghai 25
Guangzhou 24
Mexico City 24
Atlanta 23
Düsseldorf 23
Redwood City 23
Bremen 22
Brussels 22
Paris 22
Toronto 21
Berlin 20
Dakar 20
Phoenix 20
Falls Church 19
Florence 19
Rio de Janeiro 19
Wroclaw 19
Brooklyn 18
Campinas 18
Mumbai 18
Treviso 18
Ankara 17
Baghdad 17
Stockholm 17
Tashkent 17
Bangkok 16
Istanbul 16
Izmir 16
Jakarta 16
Kranj 16
Zurich 16
Bologna 14
Grafing 14
Padova 14
Totale 10.252
Nome #
Keratin14 mRNA expression in human pneumocytes during quiescence, repair and disease 465
Effect of cystic fibrosis sputum rheology on lungs drug delivery by inhalation 416
Acute respiratory distress syndrome 415
miR-200 family members reduce senescence and restore idiopathic pulmonary fibrosis type II alveolar epithelial cell transdifferentiation 368
Potential links between COVID-19-associated pulmonary aspergillosis and bronchiectasis as detected by high resolution computed tomography 357
Alveolar Epithelial Type II Cells 328
Epithelial⁻Mesenchymal Transition in the Pathogenesis of Idiopathic Pulmonary Fibrosis 325
Is early detection of late-onset Pompe disease a pneumologist’s affair? A lesson from an Italian screening study 269
Imaging review of the lung parenchymal complications in patients with IPF 234
Chronic Thromboembolic Pulmonary Hypertension: An Update 209
The History and Mystery of Alveolar Epithelial Type II Cells: Focus on Their Physiologic and Pathologic Role in Lung 197
Radiological-pathological signatures of patients with COVID-19-related pneumomediastinum: is there a role for the Sonic hedgehog and Wnt5a pathways? 197
C1q–Ha matrix regulates the local synthesis of hyaluronan in malignant pleural mesothelioma by modulating has3 expression 195
Interstitial lung disease in patients with antisynthetase syndrome: a retrospective case series study 194
Use of low field nuclear magnetic resonance to monitor lung inflammation and the amount of pathological components in the sputum of cystic fibrosis patients 192
Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO) 192
Complement protein C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma 190
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 190
Emergency Laser Treatment of a Tracheobronchial Carcinoid during ECMO 186
Low sensitivity of rapid tests detecting anti-CoV-2 IgG and IgM in health care workers’ serum for COVID-19 screening 184
Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy 183
Effect of chest physiotherapy on cystic fibrosis sputum nanostructure: an experimental and theoretical approach 177
Assessment of Treatment Effects of Aminaphtone by Capillaroscopy in a Patient with Raynaud’s Phenomenon 177
A tailored machine learning approach for mortality prediction in severe COVID-19 treated with glucocorticoids 177
Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia 176
179 C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma 175
Laser Speckle Contrast Analysis: Functional Evaluation of Microvascular Damage in Connective Tissue Diseases. Is There Evidence of Correlations With Organ Involvement, Such as Pulmonary Damage? 175
184 Complement score: A novel prognostic tool in malignant pleural mesothelioma? 172
Diagnostic Accuracy of Chest Digital Tomosynthesis in Patients Recovering after COVID-19 Pneumonia 172
Low arousal threshold: a common pathophysiological trait in patients with obstructive sleep apnea syndrome and asthma 170
The Treatment of Lung Involvement in Systemic Sclerosis 169
C1-inhibitor is a novel prognostic factor in malignant pleural mesothelioma and in serous ovarian carcinoma 166
Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker 166
Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat? 163
Deciphering loop gain complexity: a primer for understanding a pathophysiological trait of obstructive sleep apnea patients 162
Il supporto decisionale nei processi di acquisto dei broncoscopi monouso 162
Regeneration or Repair? The Role of Alveolar Epithelial Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) 161
Transbronchial lung cryobiopsy and pulmonary fibrosis: A never-ending story? 159
Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis 159
Chronic Thromboembolic Pulmonary Hypertension: An Observational Study 158
Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows 157
Complement component C1q can predict patients’ response to cisplatin depending on tumour type: A step towards personalized medicine? 154
Severe COVID‐19 ARDS Treated by Bronchoalveolar Lavage with Diluted Exogenous Pulmonary Surfactant as Salvage Therapy: In Pursuit of the Holy Grail? 150
Limited role for bronchoalveolar lavage to exclude Covid-19 after negative upper respiratory tract swabs: a multicenter study 149
Hematopoietic Stem Cell Transplantation in Late‐onset X‐linked Chronic Granulomatous Disease in a Female Carrier 146
High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients 146
High-Resolution Computed Tomography and Lung Ultrasound in Patients with Systemic Sclerosis: Which One to Choose? 146
Caution When Comparing the Impact of Corticosteroids in COVID-19 143
An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients 141
Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study 140
Cytokine Profiles as Potential Prognostic and Therapeutic Markers in SARS-CoV-2-Induced ARDS 140
Clinical Evaluation of the ButterfLife Device for Simultaneous Multiparameter Telemonitoring in Hospital and Home Settings 138
Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS) 138
Vascular Endothelial Damage in COPD: Where Are We Now, Where Will We Go? 136
Ventilatory associated barotrauma in COVID-19 patients: A multicenter observational case control study (COVI-MIX-study) 136
Successful treatment of life-threatening mycobacteriosis using adjunctive gamma-interferon therapy with genetic analysis 136
Host-Based Treatments for Severe COVID-19 135
Evaluation of Correlations between Genetic Variants and High‐Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis 135
Interstitial lung disease at high resolution ct after SARS‐COV‐2‐related acute respiratory distress syndrome according to pulmonary segmental anatomy 134
Low Arousal Threshold Estimation Predicts Failure of Mandibular Advancement Devices in Obstructive Sleep Apnea Syndrome 133
Advances in Diagnostics and Management of Respiratory System Diseases 133
Correlation between Microvascular Damage and Internal Organ Involvement in Scleroderma: Focus on Lung Damage and Endothelial Dysfunction 132
A novel technique for conducting flexible bronchoscopy cryobiopsy under conscious sedation: An observational study 130
Theory and Practice of Glucocorticoids in COVID-19: Getting to the Heart of the Matter-A Critical Review and Viewpoints 129
Correlation between Potential Risk Factors and Pulmonary Embolism in Sarcoidosis Patients Timely Treated 127
The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis 126
Comorbidities’ Effect on IPF: Pathogenesis and Management 126
Monitoring respiratory mechanics by oscillometry in COVID-19 patients receiving non-invasive respiratory support 125
Nailfold Capillaroscopy Analysis Can Add a New Perspective to Biomarker Research in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis 124
Chronic Obstructive Pulmonary Disease definition: is it time to incorporate also the concept of lung regeneration's failure? 124
Gastrointestinal Manifestations of Sarcoidosis: A State-of-the-Art, Comprehensive Review of the Literature—Practical Clinical Insights and Many Unmet Needs on Diagnosis and Treatment 123
Flt1 produced by lung endothelial cells impairs ATII cell transdifferentiation and repair in pulmonary fibrosis 123
Autoantibodies in sarcoidosis: innocent bystander or promising biomarker for organ involvement? 122
Pulmonary fibrosis: one manifestation, various diseases 122
Calcified Lung Nodules: A Diagnostic Challenge in Clinical Daily Practice 121
Valutazione dei fattori di rischio di embolia polmonare nei pazienti affetti da sarcoidosi 121
MicroRNA-200 revertono il fenotipo di pneumociti tipo II primari da fibrosi polmonare idiopatica 120
Oscillometry Longitudinal Data on COVID-19 Acute Respiratory Syndrome Treated with Non-Invasive Respiratory Support 119
Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension 117
Nailfold Video-Capillaroscopy in Sarcoidosis: New Perspectives and Challenges 117
Cardiopulmonary exercise testing complements both spirometry and nuclear imaging for assessing sarcoidosis stage and for monitoring disease activity 116
Safety of Nintedanib in a Patient with Chronic Pulmonary Fibrosis and Kidney Disease 115
Biomarkers in Systemic Sclerosis: An Overview 114
Pulmonary Sarcoidosis and Immune Dysregulation: A Pilot Study on Possible Correlation 113
Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-World Observation on Efficacy and Safety, Focus on Patients Undergoing Antithrombotic and Anticoagulant 111
Microvascular Alteration in COVID-19 Documented by Nailfold Capillaroscopy 106
Monitoraggio degli scambi gassosi e dell’equilibrio acido-base durante ventilazione meccanica 101
Pulmonary Fibrosis: one manifestation, various diseases 101
Rheumatic Diseases: Pathophysiology, Targeted Therapy, Focus on Vascular and Pulmonary Manifestations 100
OBSTRUCTIVE SLEEP APNEA SYNDROME (OSAS). WHAT’S NEW? 100
Monitoring lung mechanics by oscillometry in COVID 19 ARDS receiving non-invasive ventilation: a pilot study 97
The Updated Role of Ultrasound in Assessing Dermatological Manifestations in Systemic Sclerosis 95
Factors limiting the utility of bronchoalveolar lavage in the diagnosis of COVID-19 94
Walking the fine line between OSA and aging 91
Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study 90
Epithelial-Mesenchymal Transition: A Major Pathogenic Driver in Idiopathic Pulmonary Fibrosis? 88
What Role Does Trabecular Bone Score Play in Chronic Inflammatory Rheumatic Diseases? 87
Prognostic Value of Chest CT Volumetric Analysis in Patients with Malignant Pleural Mesothelioma 85
Obstructive Sleep Apnea Syndrome in women: gender in sleep respiratory medicine is a first step towards personalized medicine 85
Editorial: Obstructive sleep apnea syndrome (OSAS). What's new? 83
Totale 15.968
Categoria #
all - tutte 54.365
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.365


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021179 0 0 0 0 0 0 0 0 0 109 30 40
2021/2022885 55 39 69 72 58 52 100 23 126 60 56 175
2022/20231.560 135 204 154 178 115 198 56 135 189 41 108 47
2023/20241.592 93 82 125 112 139 152 315 213 49 86 139 87
2024/20253.342 79 185 236 269 265 255 197 195 407 459 391 404
2025/20268.298 825 526 675 976 747 747 1.319 397 1.055 1.031 0 0
Totale 17.459